Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $6.1 million.

  • Prime Medicine's Depreciation & Amortization (CF) rose 20.73% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 26.58%. This contributed to the annual value of $6.1 million for FY2024, which is 31.70% up from last year.
  • According to the latest figures from FY2024, Prime Medicine's Depreciation & Amortization (CF) is $6.1 million, which was up 31.70% from $4.7 million recorded in FY2023.
  • Prime Medicine's Depreciation & Amortization (CF)'s 5-year high stood at $6.1 million during FY2024, with a 5-year trough of $43,000 in FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $4.3 million, with a median of $4.7 million in 2023.
  • Data for Prime Medicine's Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 1,295.35% (in 2021) over the last 5 years.
  • Over the past 5 years, Prime Medicine's Depreciation & Amortization (CF) (Yearly) stood at $43,000 in 2020, then skyrocketed by 1,295.35% to $600,000 in 2021, then surged by 270.67% to $2.2 million in 2022, then spiked by 109.22% to $4.7 million in 2023, then skyrocketed by 31.70% to $6.1 million in 2024.